← brief for 2026-09-08 · Slowing decline

Efficacy and Safety of Baxdrostat in Hypertension: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials

Key takeaways

Baxdrostat is a new blood pressure pill. It blocks aldosterone, a hormone that raises blood pressure and strains the kidneys. This review pooled randomized trials of the drug and rated the strength of the evidence with a formal system called GRADE, which is the strongest kind of evidence there is. The trials measured blood pressure and side effects, not kidney survival, so this does not yet prove slower kidney decline. The abstract was not available in this sweep, so the exact blood pressure numbers are not listed here.

Who did this work

Muhammad Burhan (Dow University of Health Sciences) · Zain Ul Abideen Shahid (Dow University of Health Sciences) · Muhammad Abdullah Naveed (Dow University of Health Sciences) · Nitin Wathore (Gulf Medical University) · Ziyan Ansari (Civil Hospital Karachi) · Taha Ibrahim (Dow University of Health Sciences) · Syed Huzaifa Alam Raza (Dow University of Health Sciences) · Malika Abidi (Dow University of Health Sciences) · Ayesha Irshad (Dow University of Health Sciences) · Shiva Kumar (Dow University of Health Sciences) · Saad Ashraf (Dow University of Health Sciences) · Zoya Ansari (Civil Hospital Karachi)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-07
https://doi.org/10.1177/10600280261480672